selected scholarly activity
-
chapters
- Medicine Prices in the United States and Canada. 31-43. 2019
- Contemporary Issues in Pharmaceutical Patent Law. 189-202. 2017
- Instrumental Variables: Informing Policy. 61-66. 2014
- Patents and Other Incentives for Pharmaceutical Innovation. 434-442. 2014
- Chapter 11: Prescription Drug Insurance and Reimbursement 2012
- Prescription Drug Insurance and Reimbursement. 114-122. 2012
- Challenges for Causal Inference in Obesity Research 2011
- Prescription Drug Insurance and Reimbursement 2006
- A Comparison of Alternative Models of Prescription Drug Utilization. 71-86. 2002
- The Effect of Government Policy on Pharmaceutical Drug Innovation
-
conferences
- POS0149 DO POLICIES THAT IMPROVE BIOSIMILAR UPTAKE ALSO HELP ACHIEVE GREATER EXPENDITURE CONTROL? A CROSS-COUNTRY POLICY ANALYSIS. Scientific Abstracts. 534.2-53535. 2024
- Predictors of Ontario's Medication Review Program (MedsCheck Annual Service) Utilization Among Ontario Seniors. Pharmacoepidemiology and Drug Safety. 89-90. 2015
- An Examination Of Disparity In Access To Mental Health Services Among People Living With Human Immunodeficiency Virus (Hiv) And Co-Morbid Depression In Ontario. Value in Health. A145-A145. 2014
- Increased In Acute Health Care Use Among People Living With Human Immunodeficiency Virus (Hiv) And Co-Morbid Depression In Ontario: A Longitudinal Study. Value in Health. A143-A143. 2014
- DH3 THE IMPACT OF DRUG VINTAGE ON PATIENT SURVIVAL: A PATIENT-LEVEL APPROACH USING QUEBEC'S PROVINCIAL HEALTH PLAN DATA. Value in Health. A4-A5. 2008
- PEY8 ECONOMIC EVALUATION OF EARLY TREATMENT FOR PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA. Value in Health. A142-A142. 2006
- PAR9 A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE. Value in Health. A26-A27. 2005
- Estimating the price elasticity of expenditure for prescription drugs in the presence of non‐linear price schedules: an illustration from Quebec, Canada. Health Economics. 909-923. 2005
- PIN6: IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC RESISTANCE. Value in Health. 252-252. 2003
- PIN9: IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC USE AND EXPENDITURES. Value in Health. 253-254. 2003
- Alendronate co-medications may limit its use.. Clinical Pharmacology and Therapeutics. 197-197. 1998
- Health care policy evaluation using longitudinal insurance claims data: An application of the Panel Tobit estimator. Health Economics. 365-382. 1997
-
journal articles
- A costing and health-related quality of life study of high intensity focused ultrasound in primary treatment of localized low or intermediate risk prostate cancer in Ontario.. Canadian Journal of Urology. 31:11963-11970. 2024
- The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis. Health Policy. 144:105064-105064. 2024
- The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study. CANADIAN MEDICAL ASSOCIATION JOURNAL. 196:E691-E701. 2024
- The appointment-based model in community pharmacies: Patient demographics and reimbursable clinical services uptake in Ontario. Canadian Pharmacists Journal. 157:143-152. 2024
- Association between non-medical cannabis legalization and alcohol sales: Quasi-experimental evidence from Canada. Drug and Alcohol Dependence. 257:111137-111137. 2024
- Long-Term Trends in Access to Dental Care in Canada.. Journal of the Canadian Dental Association. 90:o3. 2024
- Changes in Medical Cannabis Use After Recreational Cannabis Legalization in Canada. Cannabis and Cannabinoid Research. 9:335-342. 2024
- A Systematic Review and Meta-Analysis of the Cancer. Turkish Journal of Urology. 50:1-12. 2024
- Overview of the global vaccine ecosystem. Expert Review of Vaccines. 22:749-763. 2023
- Implementation of the appointment-based model in community pharmacies: An analysis of refills and adherence. Research in Social and Administrative Pharmacy. 19:1286-1291. 2023
- AB1591 POLICY DRIVERS FOR MARKET PENETRATION OF ANTI-TNF BIOSIMILARS: MULTI-COUNTRY COMPARISONS. Annals of the Rheumatic Diseases. 82:2029-2030. 2023
- Comparison of Fracture Identification Using Different Definitions in Healthcare Administrative (Claims) Data. Pharmacy. 11:53-53. 2023
- Modeling Tiered Pricing Frameworks: A Simulation Approach. Value in Health. 26:351-358. 2023
- Lessons from 20 years of medical cannabis use in Canada. PLoS ONE. 18:e0271079-e0271079. 2023
- The impact of national income and vaccine hesitancy on country-level COVID-19 vaccine uptake. PLoS ONE. 18:e0293184-e0293184. 2023
- Pharmacy location and medical need: regional evidence from Canada. BMC Health Services Research. 22:1309. 2022
- Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review. Osteoporosis International. 33:1837-1844. 2022
- The effect of patented drug price on the share of new medicines across OECD countries. Health Policy. 126:795-801. 2022
- The Impact of Tiered-Pricing Framework on Generic Entry in Canada. International Journal of Health Policy and Management. 11:768-776. 2022
- Brand drug companies impeding generic drug company access to product samples: Estimated prevalence and impact on drug costs. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. 18:10-20. 2022
- Impact of a peer comparison intervention on seasonal influenza vaccine uptake in community pharmacy: A national cluster randomized study. Journal of the American Pharmacists Association : JAPhA. 61:539-546.e5. 2021
- Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous β‐amyloid peptide accumulation in mice. Biopharmaceutics and Drug Disposition. 42:372-388. 2021
- Factors associated with drug shortages in Canada: a retrospective cohort study. CMAJ open. 8:E535-E544. 2020
- Development and Validation of a Clinical Prediction Tool for Seasonal Influenza Vaccination in England. JAMA network open. 3:e207743-e207743. 2020
- Patient and practice level factors associated with seasonal influenza vaccine uptake among at-risk adults in England, 2011 to 2016: An age-stratified retrospective cohort study. Vaccine: X. 4:100054-100054. 2020
- <p>Stated Preferences for Attributes of a <em>CYP2C19</em> Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario</p>. ClinicoEconomics and Outcomes Research. Volume 12:167-175. 2020
- The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach. Liver International. 40:51-59. 2020
- Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet Journal of Rare Diseases. 14:12. 2019
- Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. BMJ Open. 9:e027491-e027491. 2019
- Pharmacists should counsel users of medical cannabis, but should they be dispensing it?. Canadian Pharmacists Journal. 152:10-13. 2019
- Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario. International Journal of Social Determinants of Health and Health Services. 48:702-715. 2018
- Policy to encourage the development of antimicrobials. British Journal of Clinical Governance. 23:101-110. 2018
- Estimating chronic hepatitis C prognosis using transient elastography‐based liver stiffness: A systematic review and meta‐analysis. Journal of Viral Hepatitis. 25:502-513. 2018
- Uptake and impact of regulated pharmacy technicians in Ontario community pharmacies. Canadian Pharmacists Journal. 151:197-202. 2018
- Impact of depression and recreational drug use on emergency department encounters and hospital admissions among people living with HIV in Ontario: A secondary analysis using the OHTN cohort study. PLoS ONE. 13:e0195185-e0195185. 2018
- Does rising income inequality affect mortality rates in advanced economies?. Economics. 11. 2017
- Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology. PharmacoEconomics - Open. 1:167-173. 2017
- Factors associated with mental health in Canadian Veterans. Journal of Military, Veteran and Family Health. 3:41-51. 2017
- A comparison of mechanisms for setting generic drug prices in Canada. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. 13:19-27. 2017
- The case for an essential medicines list for Canada. CANADIAN MEDICAL ASSOCIATION JOURNAL. 188:E499-E503. 2016
- Clinical and microbiological epidemiology of early and late infectious complications among solid-organ transplant recipients requiring hospitalization. Transplant International. 29:1029-1038. 2016
- Economic evaluation of vaccines in Canada: A systematic review. Human Vaccines and Immunotherapeutics. 12:1257-1264. 2016
- A Discrete Choice Experiment (Dce) To Elicit Preferences For Attributes Of A Bedside Pharmacogenetic Test – Preliminary Results. Value in Health. 18:A399-A399. 2015
- Cost Consequence Analysis of Implementing the Low Risk Ankle Rule in Emergency Departments. Annals of Emergency Medicine. 66:455-463.e4. 2015
- Determinants of chronic physical health conditions in Canadian Veterans. Journal of Military, Veteran and Family Health. 1:32-42. 2015
- Canada’s New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem. Healthcare Policy. 11:10-14. 2015
- Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology. European journal of pharmaceutics and biopharmaceutics. 94:170-179. 2015
- Intended and unintended effects of restrictions on the sale of cigarillos to youth: evidence from Canada. Tobacco Control. 24:382-388. 2015
- How Effective Is the Medicare Part D Drug Plan?. ACP journal club. 162:869-870. 2015
- Newton’s First Law as Applied to Pharmacies: Why Entry Order Matters for Generics. International Journal of the Economics of Business. 22:201-217. 2015
- The Opportunity Cost of Capital. Inquiry (United States). 52:004695801558464-004695801558464. 2015
- Validation of Six Short and Ultra-short Screening Instruments for Depression for People Living with HIV in Ontario: Results from the Ontario HIV Treatment Network Cohort Study. PLoS ONE. 10:e0142706-e0142706. 2015
- Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines. Vaccine. 32:3336-3340. 2014
- Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada. Applied Economics. 46:1081-1092. 2014
- Effect of the Low Risk Ankle Rule on the frequency of radiography in children with ankle injuries. CANADIAN MEDICAL ASSOCIATION JOURNAL. 185:E731-E738. 2013
- Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis. CMAJ open. 1:E83-E90. 2013
- Canada's Contribution to Global Research in Cardiovascular Diseases. Canadian Journal of Cardiology. 29:742-746. 2013
- Canada’s laws on pharmaceutical intellectual property: the case for fundamental reform: Figure 1:. CANADIAN MEDICAL ASSOCIATION JOURNAL. 184:543-549. 2012
- Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiology and Drug Safety. 20:838-848. 2011
- New approaches to rewarding pharmaceutical innovation. CANADIAN MEDICAL ASSOCIATION JOURNAL. 183:681-685. 2011
- The 2011 Canada-European Union Comprehensive Economic and Trade Agreement: an economic impact assessment of the EU’s proposed pharmaceutical intellectual property provisions. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. 8:81-103. 2011
- The cost of drug development: A systematic review. Health Policy. 100:4-17. 2011
- Economic instruments for obesity prevention: results of a scoping review and modified delphi survey. International Journal of Behavioral Nutrition and Physical Activity. 8:109-109. 2011
- Equity in dental care among Canadian households. International Journal for Equity in Health. 10:14-14. 2011
- Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.. Open Medicine. 5:e1-e9. 2011
- Response to Lichtenberg. Expert Review of Pharmacoeconomics and Outcomes Research. 9:505-508. 2009
- Corrigendum. Expert Review of Pharmacoeconomics and Outcomes Research. 9:492-492. 2009
- The Impact of Drug Vintage on Patient Survival: A Patient-Level Analysis Using Quebec's Provincial Health Plan Data. Value in Health. 12:847-856. 2009
- How should we support pharmaceutical innovation?. Expert Review of Pharmacoeconomics and Outcomes Research. 9:313-320. 2009
- Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Review of Pharmacoeconomics and Outcomes Research. 9:353-364. 2009
- The impact of financial incentives on pharmacist dispensing habits: Evidence from the british columbia product incentive plan. Journal of Research in Pharmaceutical Economics. 16:35-56. 2008
- Validation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the Hip. Value in Health. 11:470-477. 2008
- Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological research. Statistics in Medicine. 27:1539-1556. 2008
- Becoming the best mom that I can: women's experiences of managing depression during pregnancy – a qualitative study. BMC Women's Health. 7:13. 2007
- A review of instrumental variables estimation of treatment effects in the applied health sciences. Health Services and Outcomes Research Methodology. 7:159-179. 2007
- The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada. Health Policy. 84:1-13. 2007
- Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: A Monte Carlo study (p n/a) by Peter C. Austin, Paul Grootendorst, Sharon‐Lise T. Normand, Geoffrey M. Anderson, Statistics in Medicine, Published Online: 16 June 2006. DOI: 10.1002/sim.2618. Statistics in Medicine. 26:3208-3210. 2007
- Effect of copayments on drug use in the presence of annual payment limits.. American Journal of Managed Care. 13:328-334. 2007
- A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee.. Journal of Rheumatology. 34:534-542. 2007
- A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Statistics in Medicine. 26:734-753. 2007
- Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study. Statistics in Medicine. 26:754-768. 2007
- Response to Pazderka and Schroeder. Healthcare Policy. 2:95-96. 2007
- The Effect of Pharmaceutical Patent Term Length on Research and Development and Drug Expenditures in Canada. Healthcare Policy. 2:63-84. 2007
- Disclosure of Physician Prescribing Information and Prescription Drug Costs. Journal of Pharmaceutical Marketing and Management. 17:61-88. 2007
- Dental insurance, income and the use of dental care in Canada.. Journal of the Canadian Dental Association. 73:57. 2007
- A re‐examination of the impact of reference pricing on anti‐hypertensive drug plan expenditures in British Columbia. Health Economics. 15:735-742. 2006
- Impact of Antibiotic Administrative Restrictions on Trends in Antibiotic Resistance. Canadian Journal of Public Health. 97:126-131. 2006
- Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis. Journal of Health Services Research and Policy. 11:13-20. 2006
- National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?. Canadian Public Policy/ Analyse de Politiques. 31:341-341. 2005
- The Impact of Reference Pricing of Nonsteroidal Anti‐Inflammatory Agents on the Use and Costs of Analgesic Drugs. Health Services Research (HSR). 40:1297-1317. 2005
- The Economics of Cross-Border Trade in Pharmaceuticals. Journal of Pharmaceutical Marketing and Management. 16:99-109. 2005
- The Impact of an On-Line Pharmacy Claims Adjudication Network on Use and Costs of Prescription Drugs:. Journal of Research in Pharmaceutical Economics. 13:27-39. 2005
- Distributional effects of ‘general population’ prescription drug programs in Canada. Canadian Journal of Economics, The. 38:128-148. 2005
- Can current electronic systems meet drug safety and effectiveness requirements?. Proceedings - AMIA . Annual Symposium. AMIA Symposium. 2005:335-339. 2005
- Disclosure of Physician Prescribing Information and Prescription Drug Costs: Evidence from Saskatchewan. Journal of Pharmaceutical Marketing and Management. 17:61-87. 2005
- Resistance to antibiotics: administrative response to the challenge.. Managed Care Interface. 17:20-29. 2004
- An empirical analysis of milk addiction. Journal of Health Economics. 23:1117-1133. 2004
- Net Health Plan Savings From Reference Pricing for Angiotensin-Converting Enzyme Inhibitors in Elderly British Columbia Residents. Medical Care. 42:653-660. 2004
- Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence. International Journal of Social Determinants of Health and Health Services. 34:101-122. 2004
- The Economics of Cross-Border Trade in Pharmaceuticals: Theory and Evidence. Journal of Pharmaceutical Marketing and Management. 16:99-109. 2004
- Validity of self-reported prescription drug insurance coverage.. Health Reports. 14:35-46. 2003
- A Review of the Comprehensiveness of Provincial Drug Coverage for Canadian Seniors. Canadian Journal on Aging. 22:33-44. 2003
- Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.. Journal of Population Therapeutics and Clinical Pharmacology. 10:67-71. 2003
- Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs 2003
- Restricted access for PPIs not a panacea - Response. CANADIAN MEDICAL ASSOCIATION JOURNAL. 167:1102-+. 2002
- Restricted access for PPIs not a panacea.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 167:1102. 2002
- The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada. Journal of Health Economics. 21:805-826. 2002
- Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 166:1655-1662. 2002
- Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.. Journal of Population Therapeutics and Clinical Pharmacology. 9:79-99. 2002
- Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 165:1011-1019. 2001
- On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. Health Policy. 55:97-109. 2001
- Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapy. Pharmacoepidemiology and Drug Safety. 9:367-370. 2000
- Health Utilities Index Mark 3. Medical Care. 38:290-299. 2000
- Censoring in statistical models of health status: what happens when one can do better than '1'.. Quality of Life Research. 9:911-914. 2000
- Evaluating the impact of reference-based pricing.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 161:273-274. 1999
- Reference-based pricing (RBP) of prescription drugs.. Canadian Journal of Cardiology. 13:689-690. 1997
- On Becoming 65 in Ontario. Medical Care. 35:386-398. 1997
- Does it matter whom and how you ask? Inter- and intra-rater agreement in the Ontario Health Survey. Journal of Clinical Epidemiology. 50:127-135. 1997
- Cost analysis of dialysis treatments for end-stage renal disease (ESRD).. Clinical and Investigative Medicine. 18:455-464. 1995
- A comparison of alternative models of prescription drug utilization. Health Economics. 4:183-198. 1995
-
other
- Beneficiary cost sharing under Canadian provincial prescription drug benefit programs 1999
- Variation in pharmacare coverage across Canada 1998
- Variation in pharmacare coverage across Canada 1998
- Financial incentives to dispense low-cost drugs 1996
- Does it matter whom and how you ask? 1994
- Results of an investigation into the integrity of the Ontario Health Survey 1993
-
preprints
- The geographic distribution of pharmacies in Canada 2022
- Canada’s Laws on Pharmaceutical Intellectual Property: The Case for Fundamental Reform 2011
- An Empirical Analysis of Milk Addiction 2003
- Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs 2003
- Home Remedies: How Should Canada Acquire Vaccines for the Next Pandemic?